FDA ApprovedUnited States
New Tumor Injection for Advanced Melanoma After Immunotherapy Progresses
TUDRIQEV (vusolimogene oderparepvec-wtpg) — engineered virus injected into tumors plus nivolumab for unresectable advanced cutaneous melanoma after PD-1 therapy progress
FDA accelerated approval on 6 August 2026 for TUDRIQEV (vusolimogene oderparepvec-wtpg) suspension — a genetically modified oncolytic viral therapy for…
This is for adults with unresectable advanced cutaneous melanoma whose cancer progressed on a PD-1 immunotherapy and who may be candidates for labelled US…